Literature summary for 1.16.1.8 extracted from

Han, D.; Shen, C.; Meng, X.; Bai, J.; Chen, F.; Yu, Y.; Jin, Y.; Fu, S.
Methionine synthase reductase A66G polymorphism contributes to tumor susceptibility: evidence from 35 case-control studies (2012), Mol. Biol. Rep., 39, 805-816.

Search for more literature for 1.16.1.8

Application

Application	Comment	Organism
diagnostics	the MTRR A66G polymorphism is a potential biomarker for cancer risk	Homo sapiens

Cloned(Commentary)

Cloned (Comment)	Organism
gene MTRR, genotyping for the A66G polymorphism and analysis of the association with cancer risk, overview. The G allele and GG variant genotypes are associated with a significantly increased cancer risk	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
A66G	naturally occuring mutation, the MTRR polymorphism leads to a lower affinity for substrate methionine synthase compared to the wild-type enzyme	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Synonyms

Synonyms	Comment	Organism
Methionine synthase reductase	-	Homo sapiens
MTRR	-	Homo sapiens

General Information

General Information	Comment	Organism
metabolism	the MTRR gene is involved in tumorigenesis by regulating DNA methylation through activation of methionine synthase	Homo sapiens
additional information	genotyping for the A66G polymorphism and analysis of the association with cancer risk reveals that the G allele and GG variant genotypes are associated with a significantly increased cancer risk	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)